Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The cryptophycins: their synthesis and anticancer activity.

MariJean Eggen1, Gunda I Georg

  • 1Pharmacia Corporation, 7000 Portage Road, Kalamazoo, Michigan 49001, USA.

Medicinal Research Reviews
|February 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetic and pharmacological characterization of novel agmatine-based antihyperalgesic compounds.

The Journal of pharmacology and experimental therapeutics·2026
Same author

Development of TSSK1 and TSSK2 Targeted Degraders Reveals Sperm Machinery for Protein Degradation and Potential for Nonhormonal Male Contraception.

Journal of medicinal chemistry·2026
Same author

LKB1 Loss Sensitizes Lung Tumor Spheres to Mitomet-Induced Ferroptosis, and These Effects are Enhanced by mTOR Inhibition.

Molecular carcinogenesis·2026
Same author

Development of a Second-Generation RARα Selective Antagonist as an Orally Bioavailable, Effective, Safe, and Reversible Male Contraceptive.

Journal of medicinal chemistry·2026
Same author

Structural Basis for BD1-Preferring 2,4-Disubstituted Pyrimidine BRDT Inhibitors.

Journal of medicinal chemistry·2026
Same author

Wee1-targeting inhibitors: From virtual screening to lead discovery.

Bioorganic & medicinal chemistry·2026

Cryptophycins, potent antimitotic agents from cyanobacteria, stabilize microtubules and induce apoptosis. Modifications like gem-dimethyl substitution in cryptophycin-52 improved stability for clinical use.

Area of Science:

  • Natural Products Chemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Cryptophycins are 16-membered macrolide antimitotic agents derived from Nostoc sp. cyanobacteria.
  • They target tubulin, potently stabilizing microtubule dynamics and causing depolymerization at higher concentrations.
  • Cryptophycins also deactivate Bcl2, inducing apoptosis more rapidly and at lower doses than current clinical agents.

Purpose of the Study:

  • To explore the synthetic accessibility and structure-activity relationships of cryptophycins.
  • To address the in vivo hydrolytic instability of the C5 ester, a key challenge for clinical development.
  • To identify optimized cryptophycin analogs with improved pharmacokinetic properties.

Main Methods:

  • Convergent total synthesis strategies exploiting amide and ester linkages in the cryptophycin core.

Related Experiment Videos

  • Structure-activity relationship studies involving modifications across various regions of the molecule.
  • Chemical modification, specifically increased substitution at C6, to enhance hydrolytic stability.

    • Main Results:

    • The modular structure of cryptophycins facilitates diverse synthetic approaches and SAR studies.
    • In vivo hydrolytic instability of the C5 ester was identified as a major hurdle.
    • Gem-dimethyl substitution at C6, as seen in cryptophycin-52, successfully ameliorated ester instability.

    Conclusions:

    • Cryptophycins represent a promising class of antimitotic agents with potent biological activities.
    • Synthetic modifications, particularly at C6, are crucial for overcoming stability limitations.
    • Cryptophycin-52 demonstrates the potential for developing clinically viable cryptophycin-based therapeutics.